This is a big challenge with equally big implications. Degenerative brain diseases progress undetected for up to 20 years before detectable clinical symptoms appear. By then, a patient’s viable dopamine receptors in their brain have significantly declined, leading to diseases like Parkinson’s and Lewy Body dementia. As a result, early and accurate detection of the type of tremor is critical to taking advantage of potential therapies.
LikeMinds is taking on this challenge, by developing and commercializing an imaging agent platform capable of supporting early detection of those diseases and dysfunctions related to changes in dopamine receptor function and thereby opening the possibility of aiding in the development of disease modifying therapies in the future